Burosumab: all 25 studies that test it
Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.
- Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous DysplasiaCompletedNCT05509595Phase 2Results posted
- A Trial to Assess the Safety and Efficacy of KRN23 in Epidermal Nevus Syndrome (ENS)CompletedNCT04320316Phase 4Results posted
- Examining the Effect of Burosumab on Muscle FunctionCompletedNCT04146935Phase 4Results posted
- Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)CompletedNCT02750618Phase 2Results posted
- Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)CompletedNCT02537431Phase 3Results posted
- Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)CompletedNCT02526160Phase 3Results posted
- Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)CompletedNCT02312687Phase 2Results posted
- Study of Burosumab (KRN23) in Adults With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)CompletedNCT02304367Phase 2Results posted
- Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)CompletedNCT02163577Phase 2Results posted
- An Extension Study of KRN23 in Adults With X-Linked HypophosphatemiaCompletedNCT01571596Phase 1/2Results posted
- A Repeated Study of KRN23 in Adults With X-Linked HypophosphatemiaCompletedNCT01340482Phase 1/2Results posted
- Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIOCompletedNCT05357573Phase 4
- Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLHCompletedNCT04842032Phase 4
- Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLHCompletedNCT04842019Phase 4
- Anti-FGF23 (Burosumab) in Adult Patients With XLHCompletedNCT04695860Phase 3
- Burosumab in Children and Adolescents With X-linked HypophosphatemiaStatus unknownNCT04419363Phase 4
- A Study of KRN23 in Adult and Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedNCT04308096Phase 3
- Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of AgeCompletedNCT04188964Phase 1/2
- Burosumab for CSHSCompletedNCT03993821Early Phase 1
- Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLHCompletedNCT03920072Phase 3
- Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic RicketsCompletedNCT03581591Phase 3
- A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedNCT03233126Phase 3
- A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus SyndromeCompletedNCT02722798Phase 2
- A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/OsteomalaciaCompletedNCT02181764Phase 1
- A Study of KRN23 in X-linked HypophosphatemiaCompletedNCT00830674Phase 1